NCT07511881

Far-UVC and Infections in Long-term Care Facilities

Completed NA Last updated 6 April 2026

What this trial tests

NA trial testing Far-uvc (222 nm) in Infection in 635 participants. Completed in 30 April 2025.

Timeline

1 November 2024

Primary endpoint
30 April 2025

30 April 2025

Quick facts

Lead sponsor	Vejle Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	635
Start date	1 November 2024
Primary completion	30 April 2025
Estimated completion	30 April 2025
Sites	1 location across Denmark

Drugs / interventions tested

• Far-uvc (222 nm)
• Standard Care (Treatment as Usual) — full drug profile →

Conditions studied

• Infection — all drugs for Infection →

Sponsor

Vejle Hospital

Who can join

Eligibility, any sex, with Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background Elderly residents in long-term care (LTC) facilities are highly susceptible to infections, often leading to hospitalizations and placing significant strain on the healthcare sector. The COVID-19 pandemic underscored the importance of airborne pathogen transmission and highlighted the necessity for targeted interventions that require minimal healthcare personnel resources to protect elderly populations. Far-UVC light has emerged as a promising technology offering both germicidal efficacy and safety for human exposure, although its clinical impact remains sparsely studied. This study aims to evaluate the effectiveness of far-UVC (222 nm) in mitigating hospitalizations due to viral and bacterial infections among LTC residents.

Methods The study is designed as a controlled, phase II, multi-arm, parallel-group, superiority, 6-month trial conducted in LTC facilities in Denmark. The LTC facilities will receive either far-UVC lamps or standard care with an allocation ratio of 1:1:10. One of the LTC facilities will be equipped with far-UVC lamps (experimental arm one) in common areas, while another will be equipped with far-UVC lamps (experimental arm two) in common areas and residents' apartments. We plan to include 12 public LTC facilities in Vejle with 542 residents. Outcome data will be obtained from nationally validated health registers. The primary outcome is LTC facility-acquired infections (lower respiratory tract infections, urinary tract infections, and bloodstream infections), which cause hospitalization. The key secondary outcome is prescribed antibiotics at LTC facilities, alongside monitoring all-cause mortality, cause-specific mortality (infection), and adverse events.

Discussion This trial aims to determine the clinical impact of far-UVC technology in LTC facilities. In the case of sufficiently promising effectiveness, a large-scale cluster randomized phase III will be carried out.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. The potential effectiveness of far-UVC (222 nm) in preventing infections in long-term care facilities: a six-month nonrandomized controlled phase II trial.
   Kristensen MA, Mogensen EH, Nielsen SY, Holm CK. · · 2026 · PMID 42256834 · DOI 10.1017/ash.2026.10425